ImmunityBio, Inc.
IBRX
$2.10
-$0.44-17.32%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -413.56M | -587.79M | -597.65M | -600.96M | -583.20M |
| Total Depreciation and Amortization | 17.55M | 17.98M | 18.11M | 18.39M | 18.51M |
| Total Amortization of Deferred Charges | 22.59M | 24.70M | 29.95M | 36.41M | 42.40M |
| Total Other Non-Cash Items | 1.61M | 158.08M | 170.86M | 184.32M | 151.55M |
| Change in Net Operating Assets | -19.42M | -34.33M | -31.28M | -27.59M | 3.98M |
| Cash from Operations | -391.24M | -421.36M | -410.00M | -389.43M | -366.76M |
| Capital Expenditure | -6.89M | -12.73M | -15.62M | -23.42M | -30.58M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.36M | -7.10M | -84.88M | -34.19M | 114.00K |
| Cash from Investing | -12.25M | -19.83M | -100.49M | -57.61M | -30.47M |
| Total Debt Issued | 96.96M | 289.72M | 391.76M | 421.61M | 451.46M |
| Total Debt Repaid | -64.00K | -84.00K | -81.00K | -79.00K | -77.00K |
| Issuance of Common Stock | 190.20M | 91.83M | 115.91M | 77.10M | 110.40M |
| Repurchase of Common Stock | -5.47M | -6.22M | -7.39M | -6.95M | -3.44M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | 96.96M | -3.00K | -- |
| Cash from Financing | 281.63M | 375.24M | 597.16M | 491.68M | 558.34M |
| Foreign Exchange rate Adjustments | -23.00K | -43.00K | -55.00K | -77.00K | -292.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -121.88M | -66.00M | 86.61M | 44.56M | 160.82M |